Roche Has Many Suitors For $1.4 Bil. OTC Unit
This article was originally published in The Tan Sheet
Executive Summary
A GlaxoSmithKline/Roche consumer unit combination would have approximately $7.56 bil. in annual sales
You may also be interested in...
Roche Could Have Buyer For OTC Unit By Early Summer
Potential suitors for Roche's consumer health unit will lay out their strategy for the business next month as the divestiture process of the OTC division picks up speed
Bayer Continues Pursuit Of Aspirin Primary MI Prevention Labeling
Bayer is seeking FDA's input on how it can expand professional labeling for aspirin to include a primary myocardial infarction prevention indication
Roche OTC Business Review Raises Questions On Xenical Switch
Roche's decision to put its nonprescription business under review may indicate that a switch of its anti-obesity drug Xenical is unlikely